Critically ill patients with the pandemic H1N1 influenza who received triple the standard dose of the influenza drug oseltamivir were 7 times more likely to completely clear the virus from their system in 5 days than those who received the standard dose. This discussion addresses the healthcare implications of these findings, including a rationale for high dose therapy of sensitive strains of influenza.
Michael Schmidt, Medical Univ. of South Carolina, Charleston, SC
Anand Kumar, Hlth. Sci. Ctr., Winnipeg, MB, Canada